tirzepatide with cagrilintide A new drug combo of semaglutide (GLP-1 receptor agonist) (amylin analogue) failed to do as well as (GLP-1/GIP receptor agonist). The future of these medicines is hitting different receptors Cagrilintide 10mg — 10mg/vial Reference

Description

Tirzepatide reconstitution by vial size (units assume U-100 insulin syringes) Vial 5 mg BAC water 1.0 mL Concentration 5 mg/mL 2.5 mg 0.50 mL / 50 u 5 mg 1.00 mL / 100 u 7.5 mg 10 mg 15 mg Vial 10 mg BAC water 1.0 mL Concentration 10 mg/mL 2.5 mg 0.25 mL / 25 u 5 mg 0.50 mL / 50 u 7.5 mg 0.75 mL / 75 u 10 mg 1.00 mL / 100 u 15 mg Vial 10 mg BAC water 2.0 mL Concentration 5 mg/mL 2.5 mg 0.50 mL / 50 u 5 mg 1.00 mL / 100 u 7.5 mg 10 mg 15 mg Vial 15 mg BAC water 1.5 mL Concentration 10 mg/mL 2.5 mg 0.25 mL / 25 u 5 mg 0.50 mL / 50 u 7.5 mg 0.75 mL / 75 u 10 mg 1.00 mL / 100 u 15 mg 1.50 mL / split Vial 40 mg BAC water 2.0 mL Concentration 20 mg/mL 2.5 mg 0.125 mL / 12.5 u 5 mg 0.25 mL / 25 u 7.5 mg 0.375 mL / 37.5 u 10 mg 0.50 mL / 50 u 15 mg 0.75 mL / 75 u Vial 40 mg BAC water 3.0 mL Concentration 13.33 mg/mL 2.5 mg 0.188 mL / 18.8 u 5 mg 0.375 mL / 37.5 u 7.5 mg 0.563 mL / 56.3 u 10 mg 0.75 mL / 75 u 15 mg 1.125 mL / split Vial 60 mg BAC water 3.0 mL Concentration 20 mg/mL 2.5 mg 0.125 mL / 12.5 u 5 mg 0.25 mL / 25 u 7.5 mg 0.375 mL / 37.5 u 10 mg 0.50 mL / 50 u 15 mg 0.75 mL / 75 u 20 mg/mL keeps 40 mg and 60 mg vial setups within a 3 mL vial-capacity ceiling while keeping the listed doses compact

Anabolic-androgenic steroids and cardiovascular risk

Syringes and needles for injection ordered separately.

Still AFIB and out of control tachycardia

While this should logically increase the muscle-building effects, IGF-1 LR3 would also then bypass the internal feedback regulatory pathways, theoretically increasing the risk of negative side effects of excessive growth hormone pathway activity